Equities

GSK plc

GSK:LSE

GSK plc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2,198.00
  • Today's Change18.00 / 0.83%
  • Shares traded8.48m
  • 1 Year change48.56%
  • Beta0.7079
Data delayed at least 20 minutes, as of Feb 06 2026 14:54 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year GSK plc grew revenues 4.11% from 31.38bn to 32.67bn while net income improved 121.98% from 2.58bn to 5.72bn.
Gross margin72.67%
Net profit margin19.25%
Operating margin24.28%
Return on assets10.43%
Return on equity38.05%
Return on investment16.02%
More ▼

Cash flow in GBPView more

In 2025, cash reserves at GSK plc fell by 196.00m. However, the company earned 7.74bn from its operations for a Cash Flow Margin of 23.70%. In addition the company used 4.23bn on investing activities and also paid 3.69bn in financing cash flows.
Cash flow per share2.45
Price/Cash flow per share8.90
Book value per share4.02
Tangible book value per share-1.81
More ▼

Balance sheet in GBPView more

GSK plc has a Debt to Total Capital ratio of 52.62%, a lower figure than the previous year's 107.07%.
Current ratio0.8186
Quick ratio0.5416
Total debt/total equity1.08
Total debt/total capital0.5262
More ▼

Growth rates in GBP

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 8.20% and 123.33%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)4.51%
Div growth rate (5 year)-7.97%
Payout ratio (TTM)33.97%
EPS growth(5 years)4.62
EPS (TTM) vs
TTM 1 year ago		122.78
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.